Cyclacel Pharmaceuticals ... (CYCC)
NASDAQ: CYCC
· Real-Time Price · USD
0.26
-0.04 (-14.42%)
At close: Apr 30, 2025, 11:20 AM
-14.42% (1D)
| Bid | 0.26 |
| Market Cap | 53.87M |
| Revenue (ttm) | 43K |
| Net Income (ttm) | -9.26M |
| EPS (ttm) | -2.09 |
| PE Ratio (ttm) | -0.12 |
| Forward PE | -0.25 |
| Analyst | Buy |
| Ask | 0.26 |
| Volume | 3,201,929 |
| Avg. Volume (20D) | 2,309,503 |
| Open | 0.25 |
| Previous Close | 0.30 |
| Day's Range | 0.24 - 0.26 |
| 52-Week Range | 0.17 - 4.00 |
| Beta | 0.15 |
About CYCC
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 16, 2004
Employees 12
Stock Exchange NASDAQ
Ticker Symbol CYCC
Website https://www.cyclacel.com
Analyst Forecast
According to 1 analyst ratings, the average rating for CYCC stock is "Buy." The 12-month stock price forecast is $11, which is an increase of 4134.03% from the latest price.
Stock ForecastsNext Earnings Release
Cyclacel Pharmaceuticals Inc. is scheduled to release its earnings on May 13, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+24.02%
Cyclacel Pharmaceuticals shares are trading higher...
Unlock content with
Pro Subscription
5 months ago
+9.76%
Cyclacel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.
